Russian IP Status: Adequate, But Flawed For Pharma

In recent years, Russia has adopted IP reforms that bring its patent provisions closer to international standards, but enforcement remains problematic, as are dispute proceedings, in part because there’s a lack of trained judicial experts.

Russia officially joined the World Trade Organization (WTO) in August 2012, but it’s too early to gauge a direct impact from that event. Except for a reduction of the Russian Patent and Trademark Office’s (PTO) official fees for foreign companies, the WTO entry “had virtually no effect on the prosecution process,” says Oliver Henrion, a patent attorney in the German offices of Zellentin & Partners GBR. His firm services ChemRar High Tech Center, the Russian-US investment and research group, which is active in technology-transfer arrangements with foreign companies. (SeeAlso see "Priming Russia’s Pharma Industry For Innovation" - In Vivo, 17 May, 2013..)

Historically, IP legislation was rudimentary, but in recent years, Russia has adopted a series of intellectual property (IP) reforms that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy